Actively Recruiting
Combined Predictive Value of RSBI and CALLY Index in Predicting Weaning Success in ICU Patients
Led by Istanbul University - Cerrahpasa · Updated on 2026-05-11
105
Participants Needed
1
Research Sites
12 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The primary objective of this prospective observational study is to evaluate the effectiveness of combining the Rapid Shallow Breathing Index (RSBI) and CRP-Albumin-Lymphocyte (CALLY) index to predict weaning success in adult patients within the intensive care unit. While weaning from mechanical ventilation is a critical clinical step, existing physiological metrics like RSBI do not fully capture a patient's inflammatory or nutritional status. This research introduces the CALLY index calculated as the ratio of the patient's immuno-nutritional reserve (Albumin and Lymphocytes) to systemic inflammation (CRP) as a complementary metabolic marker. By tracking approximately 105 participants at Basaksehir Cam and Sakura City Hospital, the study monitors weaning success over both a 48 hour and a 7 day period to identify both immediate and late phase extubation failures. The ultimate goal is to provide a more holistic prediction model that potentially reduces re-intubation rates and improves clinical outcomes by accurately identifying the optimal time for ventilator removal.
CONDITIONS
Official Title
Combined Predictive Value of RSBI and CALLY Index in Predicting Weaning Success in ICU Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients aged 18 years and older
- Patients who have received invasive mechanical ventilation for at least 24 hours in the general intensive care unit
- Patients who meet standard clinical weaning criteria, such as hemodynamic stability with minimal or no vasopressor support, adequate cough reflex, and absence of excessive airway secretions
- Patients deemed ready for a Spontaneous Breathing Trial by the attending physician
You will not qualify if you...
- Patients under the age of 18
- Patients with a known or detected pregnancy
- Patients with a diagnosis of malignancy
- Patients with neuromuscular diseases that could impair respiratory effort or muscle strength assessments, such as Myasthenia Gravis, Amyotrophic Lateral Sclerosis, or Guillain-Barré syndrome
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Basaksehir Cam and Sakura City Hospital
Istanbul, Istanbul, Turkey (Türkiye), 34480
Actively Recruiting
Research Team
M
mahmut baran kasisari, medical doctor
CONTACT
T
tugba yesilyurt dogu, medical doctor
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here